Scarica l'app Stockscreener
5.25
0.57%
0.03
Precedente Chiudi:
$5.22
Aprire:
$5.23
Volume 24 ore:
669.77K
Relative Volume:
1.33
Capitalizzazione di mercato:
$264.45M
Reddito:
$230.47M
Utile/perdita netta:
$30.28M
Rapporto P/E:
8.6066
EPS:
0.61
Flusso di cassa netto:
$38.86M
1 W Prestazione:
-8.38%
1M Prestazione:
+51.30%
6M Prestazione:
+80.72%
1 anno Prestazione:
+115.16%
Intervallo 1D:
$5.04
$5.37
Intervallo di 1 settimana:
$4.81
$6.07
Portata 52W:
$2.225
$6.07
Puma Biotechnology Inc Stock (PBYI) Company Profile
Nome
Puma Biotechnology Inc
Settore
Industria
Telefono
(424) 248-6500
Indirizzo
10880 WILSHIRE BLVD., LOS ANGELES, CA
Confronta PBYI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
5.25 | 252.11M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Underperform |
| 2019-10-08 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-10 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2019-01-17 | Iniziato | Leerink Partners | Mkt Perform |
| 2019-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-11-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-11-02 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Iniziato | Goldman | Sell |
| 2018-05-11 | Reiterato | Stifel | Buy |
| 2017-11-10 | Reiterato | Citigroup | Buy |
| 2017-11-10 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Reiterato | Stifel | Buy |
| 2017-09-11 | Reiterato | Credit Suisse | Outperform |
| 2017-07-10 | Ripresa | Leerink Partners | Outperform |
| 2017-06-06 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Reiterato | RBC Capital Mkts | Sector Perform |
Mostra tutto
Puma Biotechnology Inc Borsa (PBYI) Ultime notizie
Puma Biotechnology Inc. Shows Support at Fibonacci LevelForecast Cut & Comprehensive Market Scan Reports - 선데이타임즈
Published on: 2025-08-19 05:35:25 - newsyoung.net
Live Chart Scan Detects Wedge Pattern in Puma Biotechnology Inc.Market Activity Summary & AI Forecast Swing Trade Picks - sundaytimes.kr
Puma Biotechnology (PBYI.O) Under Pressure: Technical Clues and Market Sentiment Point to Liquidity-Driven Decline - AInvest
Puma Biotechnology shares rise 2.08% premarket after Case IH unveils its highest horsepower tractor. - AInvest
What is Puma Biotechnology Inc. s revenue forecastJuly 2025 Breakouts & Weekly Top Performers Watchlists - classian.co.kr
Published on: 2025-08-16 21:30:39 - metal.it
Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT - MSN
How to build a dashboard for Puma Biotechnology Inc. stockJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - Newser
Is a relief rally coming for Puma Biotechnology Inc. holders2025 Price Targets & Free Verified High Yield Trade Plans - Newser
Puma Biotechnology shares rise 8.84% intraday after JD Sports Fashion mentions PUMA in retro football shirts article. - AInvest
Additional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong Earnings - Yahoo Finance
How to forecast Puma Biotechnology Inc. trends using time seriesAnalyst Downgrade & Safe Entry Zone Identification - Newser
Why is Puma Biotechnology Inc. stock going downWeekly Market Summary & Risk Controlled Stock Alerts - mustnews.co.kr
Published on: 2025-08-15 07:16:55 - sundaytimes.kr
Puma Biotechnology Inc. Matches Institutional Buying FilterAnalyst Upgrade & Weekly Watchlist for Consistent Profits - beatles.ru
Can trapped investors hope for a rebound in Puma Biotechnology Inc.2025 Stock Rankings & AI Enhanced Execution Alerts - Newser
Using AI based signals to follow Puma Biotechnology Inc.July 2025 Reactions & Accurate Buy Signal Alerts - Newser
Puma Biotechnology Reports Strong Q2 2025 Earnings - TipRanks
Volatility clustering patterns for Puma Biotechnology Inc.Chart Driven Opportunity Scanner with Alerts - Newser
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market - simplywall.st
Puma Biotechnology shares rise 7.22% premarket as healthcare sector earnings grow 15.4%. - AInvest
Puma Biotechnology shares get favourable price bump on strong Q2 results - Mugglehead Magazine
Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Puma Biotechnology Surges 35%: What's Fueling This Biotech Breakout? - AInvest
Riding the Waves: A Guide to Investing in PBYI Stock - investchronicle.com
10 Most Undervalued Biotech Stocks to Buy Now - Insider Monkey
Puma Biotechnology Q2 Earnings Surprise: Revenue Down 9.3%, EPS Down 54% - AInvest
Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Finance
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript - Insider Monkey
Puma Biotechnology's Q2 Earnings Outperformance and Nerlynx Momentum Signal a Strategic Buy Opportunity - AInvest
Puma Biotechnology 2025 Q2 Earnings Profitability Returns with 229.3% Net Income Surge - AInvest
Puma Biotechnology Awards Nearly 28,000 Shares to Three New Employees Under Nasdaq Rule - Stock Titan
Puma Biotechnology Q2 2025 slides: NERLYNX revenue grows 14% quarter-over-quarter - Investing.com India
Earnings call transcript: Puma Biotechnology beats Q2 2025 earnings forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Puma Biotechnology beats Q2 2025 earnings forecast - Investing.com
Puma Biotechnology Flips To Profit On Cancer Drug Sales - Finimize
Puma Biotechnology Inc (PBYI) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Puma Biotech: Q2 Earnings Snapshot - Connecticut Post
Puma Biotechnology 2025 Q2 Earnings Strong Performance as Net Income Surges 229.3% - AInvest
Puma anticipates $192M–$198M NERLYNX revenue for 2025 as company advances alisertib trials - MSN
Puma Biotechnology Reports Second Quarter 2025 Financial Results - BioSpace
Puma (PBYI) Q2 Revenue Rises 11% - AOL.com
Puma Biotechnology Reports Strong Q2 2025 Results - TipRanks
Puma Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Puma Biotechnology: Hold Rating Amid Stable Q2 Performance and Uncertain Trial Outcomes - TipRanks
Puma Biotechnology Anticipates $192M-$198M NERLYNX Revenue for 2025 Amid Alisertib Trials Advancement - AInvest
Puma Biotechnology Inc Azioni (PBYI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):